ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CGC / dividends
USNA (50) SNDL (47) ACB (54) OBIO (34) ⌘ Pro Terminal →

Canopy Growth Corporation (CGC) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.68 +4.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.68

Canopy Growth Corporation (CGC) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $276.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CGC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CGC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Canopy Growth Corporation (NASDAQ: CGC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.68 (+4.34% 1D, market cap $276.0M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, CGC ranks #442 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CGC compare to USNA and SNDL in the Health Care sector?
▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), CGC carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, USNA (USANA Health Sciences Inc.) holds a D grade (50/100 RQD, P/E 24.6x, ROIC 7.9%, cap $264.4M) and SNDL (SNDL Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $301.7M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CGC?
▼

Per CGC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001737927), Canopy Growth Corporation generated $850.5M in revenue (-46.6% YoY), -$189.0M in net income, and $0 in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.68 (+0.59%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D-
Cash (11)Whales (6)SEC (10)Macro (7)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-7.4% Base Target
$3 Bull$1 Base$0 Bear
📬 FREE CGC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CGC)Realized 20D OHLCV Swing Band: ±12%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY CGC SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+11/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0.9% FCF Margin ($7.7M FCF) & 46.7% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
49
Grade D$0.76-5.3% Next Q
Q2 (-2Q)
46
Grade D$0.72-5.6% Next Q
Q3 (-1Q)
44
Grade D$0.68+0% Next Q
Current
41
Grade D-$0.68-7.2% Hist 90D α
Trajectory: D (49) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CGC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CGC currently carries a cautious 41/100 (D-) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.86) and Max Pain ($0.71) forces dealer call-delta covering toward $2.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CGC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CGC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CGC)

  • ✓Walkthrough of CGC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CGC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.18%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.67H $0.68L $0.65C $0.68VOL 2.28M
RES: $1.03SUP: $0.63SMA50: $0.86SMA200: $0.99
$1.26$1.09$0.92$0.76$0.59RES $1.03SUP $0.63$0.682026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CGC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CGC Butterfly Map → + Track CGC →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -46.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CGC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CGC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CGC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CGC)

Health Care Rank #442 of 1015 ⚔️ USNA vs CGC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CGC vs. USNA, SNDL, ACB, OBIO)

Industry: Medicinal Chemicals and Botanical Products (23 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Canopy Growth Corporation (CGC) ranks #442 by composite RQD confidence (41/100, grade D-) and #525 by equity capitalization ($276.0M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. ACB currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with CGC at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CGC ACTIVE
Canopy Growth Corporation
D- 41/100 — — — +4.34% $276.0M Benchmark Subject
USNA
USANA Health Sciences Inc.
D 50/100 24.6x 78.3% 7.9% +2.87% $264.4M /usna-vs-cgc →
SNDL
SNDL Inc.
D 47/100 — — — +2.42% $301.7M /sndl-vs-cgc →
ACB
Aurora Cannabis Inc.
D+ 54/100 — — — +3.94% $251.5M /acb-vs-cgc →
OBIO
Orchestra BioMed Holdings Inc.
E 34/100 — 96.0% -35.0% -3.72% $355.2M /obio-vs-cgc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001737927 ↗

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Canopy Growth Corporation (CGC) reported GAAP revenue of $850.5M (-46.6% vs. FY2024 revenue of $1.59B , and -64.1% cumulative change since FY2023) , GAAP net income of -$189.0M, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, CGC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-03-31 $850.5M -$189.0M — — — —
FY2024 (FY) 2025-03-31 $1.59B -$354.0M — — — —
FY2023 (FY) 2024-03-31 $2.37B -$526.0M — — — —

3. CGC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CGC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Canopy Growth Corporation (NASDAQ: CGC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.68 (+4.34% 1D, market cap $276.0M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, CGC ranks #442 in composite RQD confidence.

How does CGC compare to USNA and SNDL in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), CGC carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, USNA (USANA Health Sciences Inc.) holds a D grade (50/100 RQD, P/E 24.6x, ROIC 7.9%, cap $264.4M) and SNDL (SNDL Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $301.7M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CGC?

Per CGC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001737927), Canopy Growth Corporation generated $850.5M in revenue (-46.6% YoY), -$189.0M in net income, and $0 in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CGC trading relative to its 50-day, 200-day, and 52-week technical levels?

CGC last traded at $0.68 (+4.34% on volume of 1,907,190 shares), positioning the stock -20.93% below its 50-day simple moving average ($0.86) and -31.31% below its 200-day simple moving average ($0.99). Across its 52-week range of $0.64 to $2.38, CGC sits at the 2.3% percentile with a 14-day RSI of 29.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.0% ($1.00 to $0.76).

Direct Sub-Reports: CGC RQD Cockpit CGC 12M Forecast CGC Earnings & Move CGC Dividends & DRIP CGC Insiders & 13F CGC Whale Options CGC Profit Sankey CGC News & Why
ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CGC — Canopy Growth Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-03-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Canopy Growth Corporation (CGC) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.68 (+4.34% 1D, market capitalization $276.0M).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Canopy Growth Corporation is listed on NASDAQ under the ticker CGC.. Customer base, product lines, and revenue model are — The profile reports a market capitalization of $0.3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), Canopy Growth Corporation (CGC) reported $850.5M in annual revenue (up from $1.59B in FY2024, -46.6% YoY) and -$189.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.37B revenue, -$526.0M net income) through FY2025, CGC scaled operating cash flow to $0 and free cash flow to $0, backed by $0 in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.64 – $2.38 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medicinal Chemicals and Botanical Products (Health Care), CGC carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can CGC sustain or expand its — operating margin and — ROIC against Medicinal Chemicals and Botanical Products peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $850.5M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CGC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CGC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Canopy Growth Corporation (CGC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CGC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CGC Bull vs. Bear Conversation Board — What's Your Call at $0.68?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CGC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CGC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $0.79 (+21.5%)
📌 Pinned Debate

Shareholders have authorized a reverse split of up to 1-for-15, a step that could address the sub-$1 listing compliance issue flagged i

Shareholders have authorized a reverse split of up to 1-for-15, a step that could address the sub-$1 listing compliance issue flagged in the news flow.. When you look under the hood at CGC, Fundamental Cash Engine is 11/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (6/20) has been quietly accumulating below $2.38. My 12M target is $0.79.

VolSurface_Trader 🐂 BULL

@MultipleCompression Shorting a 6/20 institutional whale-flow stock at $0.65 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $0.52 (-20.0%)
Spot @ $0.65

The RQD rating of 41 (D-) is driven by 0% ROIC, 0% FCF yield, and a Piotroski F-Score of 1 out of 9, with net losses reported in each o

Fading this rally in CGC at $0.65. The RQD rating of 41 (D-) is driven by 0% ROIC, 0% FCF yield, and a Piotroski F-Score of 1 out of 9, with net losses reported in each of the three fiscal years provided.. With a beta of 1.0 and the stock sitting at $0.65 (52-wk range $0.64–$2.38), the easy multiple expansion is already priced in.

LIVE TAPE